• 1
    Gehlbach SH, Avrunin JS, Puleo E. Trends in hospital care for hip fractures. Osteoporos Int. 2007 May; 18(5):58591.
  • 2
    Melton LJ3rd. Cooper C. Magnitude and impact of osteoporosis and fractures In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego: Academic Press; 2001: p. 55767.
  • 3
    Shim RS, Baltrus P, Ye J, Rust G. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005–2008. J Am Board Fam Med. 2011 Jan-Feb; 24(1):338.
  • 4
    Wu Q, Magnus JH, Liu J, Bencaz AF, Hentz JG. Depression and low bone mineral density: a meta-analysis of epidemiologic studies. Osteoporos Int. 2009 Aug; 20(8):130920.
  • 5
    Wu Q, Liu J, Gallegos-Orozco JF, Hentz JG. Depression, fracture risk, and bone loss: a meta-analysis of cohort studies. Osteoporos Int. 2010 Oct; 21(10):162735.
  • 6
    Wu Q, Bencaz AF, Hentz JG, Crowell MD. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int. 2012 Jan; 23(1):36575.
  • 7
    Ray WA. Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol. 1992 Dec; 12(6):38696.
  • 8
    Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998 Sep 24; 339(13):87582.
  • 9
    Ensrud KE, Blackwell T, Mangione CM, Bowman PJ, Bauer DC, Schwartz A, Hanlon JT, Nevitt MC, Whooley MA. Study of Osteoporotic Fractures Research Group. Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 2003 Apr 28; 163(8):94957.
  • 10
    Lewis CE, Ewing SK, Taylor BC, Shikany JM, Fink HA, Ensrud KE, Barrett-Connor E, Cummings SR, Orwoll E. Osteoporotic Fractures in Men (MrOS) Study Research Group. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res. 2007 Feb; 22(2):2119.
  • 11
    Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008 Aug; 28(4):4117.
  • 12
    Diem SJ, Blackwell TL, Stone KL, Cauley JA, Hillier TA, Haney EM, Ensrud KE. Study of Osteoporotic Fractures Research Group. Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int. 2011 Jun; 88(6):47684.
  • 13
    Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011 Aug 2; 343:d4551.
  • 14
    Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ3rd. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987 Feb 12; 316(7):3639.
  • 15
    Ray WA, Griffin MR, Malcolm E. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med. 1991 Apr; 151(4):7546.
  • 16
    Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998; May 2; 351(9112):13037.
  • 17
    Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003 Jul 1; 158(1):7784.
  • 18
    Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17(6):80716.
  • 19
    van den Brand MW, Pouwels S, Samson MM, van Staa TP, Thio B, Cooper C, Leufkens HG, Egberts AC, Verhaar HJ, de Vries F. Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int. 2009 Oct; 20(10):170513. Erratum in: Osteoporos Int. 2009 Oct; 20(10) 1715.
  • 20
    Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone. 2010 Sep; 47(3):6049.
  • 21
    Vestergaard P. Fracture risks of antidepressants. Expert Rev Neurother. 2009 Jan; 9(1):13741.
  • 22
    Ginzburg R, Rosero E. Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants. Ann Pharmacother. 2009 Jan; 43(1):98103.
  • 23
    Rizzoli R, Cooper C, Reginster JY, Abrahamsen B, Adachi JD, Brandi ML, Bruyère O, Compston J, Ducy P, Ferrari S, Harvey NC, Kanis JA, Karsenty G, Laslop A, Rabenda V, Vestergaard P. Antidepressant medications and osteoporosis. Bone. 2012 Sep; 51(3):60613.
  • 24
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000 Apr 19; 283(15):200812.
  • 25
    Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009 Aug 18; 151(4):2649, W64.
  • 26
    Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta analyses [Internet]. Ottawa, ON, Canada: Ottawa Hospital Research Institute. 2011. [cited 2012 Nov 14]. Available from:
  • 27
    Walter SD, Cook RJ. A comparison of several point estimators of the odds ratio in a single 2 × 2 contingency table. Biometrics. 1991 Sep; 47(3):795811.
  • 28
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; Jun 15; 21(11):153958.
  • 29
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6; 327(7414):55760.
  • 30
    Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the ‘number needed to treat’?: an empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 2002 Feb; 31(1):726.
  • 31
    Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000 Nov; 53(11):111929.
  • 32
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 Dec; 50(4):1088101.
  • 33
    Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; Jun; 56(2):45563.
  • 34
    Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007 Nov 10; 26(25):454462.
  • 35
    Ruzni N, Idris N. Performance of the trim and fill method in adjusting for the publication bias in meta-analysis of continuous data. Am J Appl Sci. 2012;9(9):15127.
  • 36
    Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007 Jun 25; 167(12):12405.
  • 37
    Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging. 2009;26(5):38194.
  • 38
    Christensen P, Thomsen HY, Pedersen OL, Gram LF, Kragh-Sorensen P. Orthostatic side effects of clomipramine and citalopram during treatment for depression. Psychopharmacology (Berl). 1985;86(4):3835.
  • 39
    Rodriguez de la Torre B, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H, Luderitz B, Rao ML. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit. 2001 Aug; 23(4):43540.
  • 40
    Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry. 1999; 60 Suppl 20:48.
  • 41
    Katz G. Tachyphylaxis/tolerance to antidepressive medications: a review. Isr J Psychiatry Relat Sci. 2011;48(2):12935.
  • 42
    Mitchell PB, Mitchell MS. The management of depression. Part 2. The place of the new antidepressants. Aust Fam Physician. 1994 Sep; 23(9): 1771-3, 177681.
  • 43
    Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O'Malley PG. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010 Oct 20; 341:c5222.
  • 44
    Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009 Apr 7; 15(13):15483.
  • 45
    Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007 Jul 14; 335(7610):87.
  • 46
    Romas E. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol. 2005 Dec; 19(6):106579.
  • 47
    Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol. 2004 Mar; 38(3):21824.
  • 48
    Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH. Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005 Dec; 118(12):1414.